Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neuphoria Therapeutics (NEUP) Cash & Equivalents (2020 - 2025)

Neuphoria Therapeutics (NEUP) has disclosed Cash & Equivalents for 5 consecutive years, with $22.2 million as the latest value for Q4 2025.

  • Quarterly Cash & Equivalents rose 410.98% to $22.2 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $22.2 million through Dec 2025, up 410.98% year-over-year, with the annual reading at $14.2 million for FY2025, N/A changed from the prior year.
  • Cash & Equivalents for Q4 2025 was $22.2 million at Neuphoria Therapeutics, up from $13.6 million in the prior quarter.
  • The five-year high for Cash & Equivalents was $24.0 million in Q2 2022, with the low at $4.3 million in Q4 2024.
  • Average Cash & Equivalents over 4 years is $14.5 million, with a median of $13.9 million recorded in 2025.
  • The sharpest move saw Cash & Equivalents crashed 49.26% in 2023, then surged 410.98% in 2025.
  • Over 4 years, Cash & Equivalents stood at $24.0 million in 2022, then plummeted by 49.26% to $12.2 million in 2023, then plummeted by 64.38% to $4.3 million in 2024, then soared by 410.98% to $22.2 million in 2025.
  • According to Business Quant data, Cash & Equivalents over the past three periods came in at $22.2 million, $13.6 million, and $14.2 million for Q4 2025, Q3 2025, and Q2 2025 respectively.